Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To compare the proportion of patients free from progression 9 months from the start of
consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel
alone. For the purposes of this protocol, "consolidation" therapy refers to treatment given
at the time of maximal benefit from conventional front-line multi-agent chemotherapy.
Secondary Objective:
1. To compare time to progression (TTP), overall survival (OS) and cause-specific survival
(CSS) in the two arms. For completeness, these will be reported both from the initiation of
consolidation chemotherapy, and from the completion of induction chemotherapy.